Showing results (211-220 of 340) with videos related to
Sort By:
Pageof 34
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|July 26, 2015
Prognostic clinical and molecular biomarkers of renal disease in type 2 diabetesMichelle J Pena, Dick de Zeeuw, Harald Mischak, et al.Diabetes, Obesity & Metabolism|March 1, 2017
Optimizing the analysis strategy for the CANVAS Program: A prespecified plan for the integrated analyses of the CANVAS and CANVAS-R trialsBruce Neal, Vlado Perkovic, Kenneth W Mahaffey, et al.Diabetologia|August 11, 2019
Canagliflozin and fracture risk in individuals with type 2 diabetes: results from the CANVAS ProgramZien Zhou, Meg Jardine, Vlado Perkovic, et al.Lancet (London, England)|March 3, 2009
Effect of lowering blood pressure on cardiovascular events and mortality in patients on dialysis: a systematic review and meta-analysis of randomised controlled trialsHiddo J Lambers Heerspink, Toshiharu Ninomiya, Sophia Zoungas, et al.JACC. Heart Failure|November 3, 2019
Mediators of the Effects of Canagliflozin on Heart Failure in Patients With Type 2 DiabetesJingWei Li, Mark Woodward, Vlado Perkovic, et al.Life Sciences|August 1, 2002
Normalization of aortic function during arousal episodes in the hibernating ground squirrelRobert H Henning, Leo E Deelman, Roelof A Hut, et al.Journal of the American Society of Nephrology : JASN|September 19, 2019
Effect of Canagliflozin on Renal and Cardiovascular Outcomes across Different Levels of Albuminuria: Data from the CANVAS ProgramBrendon L Neuen, Toshiaki Ohkuma, Bruce Neal, et al.Pharmacoeconomics|June 10, 2006
Pharmacoeconomics of angiotensin II antagonists in type 2 diabetic patients with nephropathy: implications for decision makingCornelis Boersma, Jarir Atthobari, Ron T Gansevoort, et al.Hypertension (Dallas, Tex. : 1979)|June 3, 2011
Effect of a reduction in uric acid on renal outcomes during losartan treatment: a post hoc analysis of the reduction of endpoints in non-insulin-dependent diabetes mellitus with the Angiotensin II Antagonist Losartan TrialYan Miao, Stefan A Ottenbros, Goos D Laverman, et al.Diabetes, Obesity & Metabolism|July 11, 2018
N-terminal pro-brain natriuretic peptide (NT-proBNP) predicts the cardio-renal response to aliskiren in patients with type 2 diabetes at high renal and cardiovascular riskNienke M A Idzerda, Frederik Persson, Michelle J Pena, et al.Pageof 34